News | Mammography | October 23, 2019

Cancer detection rates measure higher with DBT versus digital mammography regardless of tumor type, size or grade of cancer

Breast Tomosynthesis Increases Cancer Detection Over Digital Mammography

October 23, 2019 — Screening digital breast tomosynthesis (DBT) results in “significantly increased CDR [cancer detection rates]” compared to full-field digital mammography (FFDM), according to an ahead-of-print article in the March issue of the American Journal of Roentgenology (AJR).[1] DBT offered improved results irrespective of tumor type, size or grade of cancer.

Reviewing consecutive screening examinations performed between October 2012 and September 2014 at a large academic breast imaging practice, Pragya A. Dang, M.D., and researchers at Brigham and Women’s Hospital in Boston detected 61 cancers in the matched cohort of DBT (n = 9817) and FFDM (n = 14,180) examinations. 

CDR measured higher with DBT than with FFDM for invasive cancers (2.8 vs 1.3, p = 0.01), minimal cancers (2.4 vs 1.2, p = 0.03), estrogen receptor–positive invasive cancers (2.6 vs 1.1, p = 0.01), and node-negative invasive cancers (2.3 vs 1.1, p = 0.02.), respectively. 

However, the ratio of screen-detected invasive cancers to ductal carcinoma in situ on DBT (3.0) was not significantly different from that on FFDM (2.6) (p = 0.79).

Comparison of Overall Cancer Detection Rates of DBT and FFDM

Note—DCIS = ductal carcinoma in situ.

a —Values are rate per 1000 with number of examinations in parentheses.

b — Values in bold are statistically significant.

 

Where CDR were not statistically significant for DBT and FFDM, Dang noted, “We were likely underpowered to show a significant difference because of the smaller number of cancers in these subgroups. For instance, CDR of moderately and poorly differentiated invasive cancers, and for all cancer sizes detected with DBT, was nearly twice that of FFDM, even though it was not statistically significant.”

As Dang concluded, “our results suggest that integrating DBT into clinical practice may detect overall more cancers than does FFDM, for all tumor sub-types, grades, sizes and nodal statuses.”

For more information: www.ajronline.org

Reference

1. Dang P.A., Wang A., Senapati G.M., et al. Comparing Tumor Characteristics and Rates of Breast Cancers Detected by Screening Digital Breast Tomosynthesis and Full-Field Digital Mammography. American Journal of Roentgenology, published online Oct. 15, 2019. DOI: 10.2214/AJR.18.21060


Related Content

News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
Subscribe Now